Abstract:PURPOSE:To explore the clinical efficacy and safety of Licartin combined with transcatheter hepatic arterial chemoembolization (TACE) in the treatment of middle-advanced primary liver cancer.METHODS:The clinical data of 112 patients with middle-advanced primary liver cancer treated in our hospital from March 2015 to March 2017 were collected. Fifty-six patients underwent TACE combined with Licartin (Licartin+TACE group), while the remaining 56 patients were treated with TACE alone (TACE group). The short-term efficacy, peripheral hemogram, liver function, alpha fetoprotein (AFP) level, count of circulating tumor cells (CTCs) and cluster of differentiation (CD)147 phenotype before and after treatment were assessed in both groups, the incidence of adverse reactions was compared, and the postoperative survival and disease development were recorded during follow-up.RESULTS:At 2 weeks after treatment, the levels of ALT and AST were significantly higher in Licartin + TACE group than those in TACE group (p<0.05). After treatment, the white blood cell count (WBC) and platelet count (PLT) obviously declined in both groups, and they were obviously lower in Licartin + TACE group than those in TACE group (p<0.05). After treatment, the count of CTCs evidently declined in both groups compared with that before treatment (p<0.05), and it was evidently lower in Licartin + TACE group than in TACE group (p<0.001). All patients were followed up for 3-36 months. In Licartin + TACE group and TACE group, the mean overall survival (OS) was 13.1±3.6 months and 11.3±2.8 months, respectively, and the mean progression-free survival (PFS) was 7.9±1.4 months and 6.1±1.2 months, respectively. At the end of follow-up, the Kaplan-Meier survival curves were plotted and log-rank test found that the OS rate was remarkably superior in Licartin + TACE group to that in TACE group (p=0.047), but the PFS rate had no statistically significant difference between the two groups (p=0.372).CONCLUSIONS:Licartin combined with TACE has better efficacy than TACE alone in the treatment of middle-advanced primary liver cancer, with tolerable adverse reactions, which prolongs patients' survival time.

Imaging and Biodistribution of Licartin in Human Body

Pharmacokinetics of ~(131)I-Labeled-metuximab and Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma

The experimental study on biodistribution and radioimmunoimaging of 131I labeled anti-lymphoma Fab antibody in nude mice bearing human B cell lymphoma

Analysis of factors influencing the distribution of 131-I in combined treatment of Licartin with transcatheter arterial chemoembolization in primary hepatic carcinoma

Efficacy of Licartin Combined with Transcatheter Hepatic Arterial Chemoembolization in the Treatment of Middle-Advanced Primary Liver Cancer.

Radioimmunoimaging of human hepatocellular carcinoma xenografts with 131I-anti-HBx monoclonal antibody

An Experimental Study on Mice Bearing Liver Cancer Imaging with ~(99)Tc~m-Hl91

131 I-Labeled-Metuximab Plus Transarterial Chemoembolization in Combination Therapy for Unresectable Hepatocellular Carcinoma: Results from a Multicenter Phase IV Clinical Study.

Biodistribution of iodine-131-labled chimeric monoclonal antibody in patients following intratumoral administraion in advanced lung carcinoma

A randomized controlled trial of licartin for preventing hepatoma recurrence after liver transplantation

A Novel Tc-99m-Labeled Molecular Probe For Tumor Angiogenesis Imaging In Hepatoma Xenografts Model: A Pilot Study

Radioimmunoimaging and Biodistribution of ~(131)I Labeled Anti-Cea Monoclonal Antibody C50 in Nude Mice Bearing Human Breast Carcinoma Xenografts

Radioiodinated Anti-Hepatocellular Carcinoma (HCC) Ferritin Targeting Therapy, Tumor Imaging and Anti-Antibody Response in HCC Patients with Hepatic Arterial Infusion

Treatment of Hepatocellular Carcinoma by Intratumoral Injection of 125I-AA98 Mab and Its Efficacy Assessments by Molecular Imaging.

Biodistribution and Imaging of Radioiodinate Antihuman Tumor-derived IgG Light Chain Monoclonal Antibody in Nude Mice Bearing Tumor in Vivo

A Novel 99mTc-Labeled Molecular Probe for Tumor Angiogenesis Imaging in Hepatoma Xenografts Model:A Preliminary Study

Tumor Radioimmunoimaging of Chimeric Antibody in Nude Mice with Hepatoma Xenograft.

Evaluation of radioimmunoimaging during radioimmunotherapy with monoclonal anti-human hepatocellular carcinoma antibodies

Tc-99m-Labeled Bombesin(7-14)Nh2 With Favorable Properties For Spect Imaging Of Colon Cancer

~(125)I/~(111)in Labeled Anti-EGFR Monoclonal Antibody Panitumumab:Preparation and Biodistribution Evaluation in Normal Mice

Construction of in-situ self-assembled agent for NIR/PET dual-modal imaging and photodynamic therapy for hepatocellular cancer